Fresenius Medical Care AG & Co. KGaA
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Fresenius Medical Care AG & Co. KGaA, the world's leading provider of dialysis products and services, offers a comprehensive portfolio along the entire dialysis value chain, including dialysis machines such as the 2008T BlueStar and Liberty Select systems, dialyzers like Optiflux, reverse osmosis water purification systems, renal pharmaceuticals, therapeutic apheresis solutions, and related disposables and supplies; it operates approximately 3,700 dialysis clinics serving over 299,000 patients worldwide as of December 2024, with around 40 production sites across all continents and a dominant 38% market share in the US dialysis sector. Founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care, the company maintains global headquarters in Bad Homburg vor der Höhe, Germany, North American headquarters in Waltham, Massachusetts, and regional hubs in Hong Kong for Asia-Pacific and Rio de Janeiro for Latin America; it focuses on chronic and acute kidney disease treatments for end-stage renal disease patients, primarily through outpatient centers, value-based care models, and care enablement services targeting nephrologists and healthcare providers in North America, Europe, Asia-Pacific, and Latin America. In recent developments, Fresenius Medical Care advances its FME Reignite strategy by investing EUR 312 million in September 2025 to increase ownership in Interwell Health, a renal value-based care leader, accelerating vertical integration following the 2022 merger of Cricket Health, Interwell Health, and Fresenius Health Partners; it divests select kidney disease laboratory testing assets of Spectra Laboratories to Quest Diagnostics in early 2025 to enhance operational efficiencies; and launches the FME Reignite strategy in June 2025 to strengthen core operations, drive innovation, and improve cash flow with planned annual capex of EUR 800 million to EUR 1 billion through 2030.
FMS and Home Dialysis: How 5008X Could Reset Demand
FMS Launches kinexus Digital Platform for Home Dialysis Care
Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
Toronto Stock Exchange, Focus Graphite Inc., The View from the C-Suite
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
FMS Stock Rises Despite Q1 Earnings & Sales Miss, Margins Expand
Fresenius Medical Care AG (FMS) Q1 2026 Earnings Call Transcript
Fresenius Medical: The Undervaluation Is Getting Clearer
Fresenius Medical Care delivers strong operating income growth in Q1 2026 while advancing the U.S. rollout of 5008X CAREsystems at speed
Fresenius Medical Care Posts Lower Net Profit on One-Off Costs
Fresenius Medical Care's revenue falls in Q1 as weak dollar takes toll
Is JB Hunt Transport Services (JBHT) 29.2% Overvalued After Q1 2026 Earnings Beat? EPS $1.49 vs $1.45 est; Revenue $3.06B vs $2.94B est - GF Score 87/100
Reviewing Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Bluejay Diagnostics (NASDAQ:BJDX)
Why Fresenius (FMS) is a Top Value Stock for the Long-Term